

=> d his

(FILE 'HOME' ENTERED AT 15:26:06 ON 08 JUN 2005)

FILE 'HCAPLUS' ENTERED AT 15:26:12 ON 08 JUN 2005

L1 1 US20040127396/PN OR US2000-213995#/AP, PRN

L2 1 (US20040127396 OR CA2312109)/PN OR US2000-213995#/AP, PRN

FILE 'REGISTRY' ENTERED AT 15:28:06 ON 08 JUN 2005

FILE 'HCAPLUS' ENTERED AT 15:28:09 ON 08 JUN 2005

L3 TRA L2 1- RN : 10 TERMS

FILE 'REGISTRY' ENTERED AT 15:28:10 ON 08 JUN 2005

L4 10 SEA L3

FILE 'WPIX' ENTERED AT 15:28:16 ON 08 JUN 2005

L5 1 (US20040127396 OR CA2312109)/PN OR US2000-213995#/AP, PRN

=> b hcap

FILE 'HCAPLUS' ENTERED AT 15:28:41 ON 08 JUN 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Jun 2005 VOL 142 ISS 24

FILE LAST UPDATED: 7 Jun 2005 (20050607/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all l2 tot/

L2 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:533954 HCAPLUS

DN 141:82318

ED Entered STN: 02 Jul 2004

TI Use of furin and furin-like protease inhibitors in the treatment of inflammatory or matrix remodelling diseases

IN Dubois, Claire

PA Can.

SO U.S. Pat. Appl. Publ., 22 pp.

CODEN: USXXCO

DT Patent

LA English

IC ICM A61K038-17

INCL 514002000

CC 1-7 (Pharmacology)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004127396	A1	20040701	US 2001-885914	20010622 <--
	CA 2312109	AA	20011223	CA 2000-2312109	20000623 <--

Search done by Noble Jarrell

PRAI CA 2000-2312109 A 20000623  
 US 2000-213995P P 20000626 <--

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004127396	ICM	A61K038-17
	INCL	514002000
US 2004127396	NCL	514/002.000
	ECLA	A61K038/57 <--
CA 2312109	ECLA	A61K038/57 <--

AB The present invention provides methods, uses and compns. of an  $\alpha$ 1-antitrypsin variant called PDX or a construct, variant, analog, peptide, peptidomimetic, salt, complex or derivative thereof for the treatment of inflammatory or erosive diseases such as rheumatoid arthritis. PDX inhibited collagen-induced arthritis in female Lewis rats.

ST furin protease inhibitor treatment inflammation; matrix remodelling disease treatment furin protease inhibitor; PDX treatment rheumatoid arthritis

IT ~~Peptidomimetics~~  
~~(PDX-related)~~ furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases)

IT ~~Peptides~~, biological studies  
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
~~(PDX-related)~~ furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases)

IT Cell proliferation  
 (blocking of proprotein convertase-mediated; furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases)

IT Drug delivery systems  
 (carriers, intracellular; furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases)

IT Disease, animal  
 (erosive, treatment of; furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases)

IT Gene  
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (for PDX; furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases)

IT Adenoviral vectors  
~~Anti-inflammatory agents~~  
~~Antiarthritics~~  
~~Antirheumatic agents~~  
~~Drug delivery systems~~  
~~Gene therapy~~  
 Human

Mammalia  
 Transformation, genetic  
 (furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases)

IT Drug delivery systems  
 (prodrugs; furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases)

IT ~~Platelet-derived growth factors~~  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (proprotein convertase-mediated endoproteolytic activation of mature, blocking of; furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases)

IT Extracellular matrix  
 (remodelling diseases, treatment of; furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases)

IT Synovial membrane  
 (synoviocyte, recombinant PDX production in rat; furin and furin-like

- protease inhibitors in treatment of inflammatory or matrix remodelling diseases)
- IT ~~inflammation~~  
~~Rheumatoid arthritis~~  
(treatment of; furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases)
- IT ~~transforming growth factors~~  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
( $\beta$ -), proprotein convertase-mediated endoproteolytic activation of, blocking of; furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases)
- IT ~~Transforming growth factors~~  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
( $\beta$ 1-, PDX inhibition of furin-mediated processing of human; furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases)
- IT 146480-35-5, Gelatinase A  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(PDX inhibition of furin-mediated processing of; furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases)
- IT 9041-92-3DP,  $\alpha$ 1-Antitrypsin, PDX mutant  
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(furin inhibitor; furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases)
- IT 9041-92-3D, PDX-mutant, analogs, salts, complexes, derivs.  
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(furin inhibitor; furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases)
- IT 99676-46-7, Proprotein convertase, 141760-45-4, Furin  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitors; furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases)
- IT 141769-16-3, TACE  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(proprotein convertase-mediated endoproteolytic activation of, blocking of; furin and furin-like protease inhibitors in treatment of inflammatory or matrix remodelling diseases)
- IT 257637-28-8 257904-58-8 476616-83-8 714399-15-2  
RL: PRP (Properties)  
(unclaimed sequence; use of furin and furin-like protease inhibitors in the treatment of inflammatory or matrix remodelling diseases)

=> b reg

FILE 'REGISTRY' ENTERED AT 15:28:52 ON 08 JUN 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 JUN 2005 HIGHEST RN 851848-50-5  
DICTIONARY FILE UPDATES: 7 JUN 2005 HIGHEST RN 851848-50-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

~~Seq~~ ide 14 tot

L4 ANSWER 1 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 714399-15-2 REGISTRY  
ED Entered STN: 22 Jul 2004  
CN Peptide, (Arg-Xaa-Xaa-Arg) (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 4: PN: US20040127396 PAGE: 1 unclaimed sequence  
FS PROTEIN SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL


\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 2 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 476616-83-8 REGISTRY  
ED Entered STN: 18 Dec 2002  
CN L-Arginine, L-arginyl-L-valyl-L-lysyl- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 1: PN: WO2004043385 PAGE: 15 unclaimed sequence  
CN 3: PN: US20040127396 SEQID: 3 unclaimed sequence  
CN 4: PN: WO02094994 SEQID: 8 unclaimed sequence  
CN 52: PN: EP1475435 SEQID: 52 unclaimed sequence  
FS PROTEIN SEQUENCE; STEREOSEARCH  
MF C23 H47 N11 O5  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1907 TO DATE)  
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 3 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 257904-58-8 REGISTRY  
ED Entered STN: 03 Mar 2000  
CN L-Methionine, L-alanyl-L-isoleucyl-L-prolyl- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 13: PN: US6022855 SEQID: 7 unclaimed sequence  
CN 1: PN: US20040127396 SEQID: 1 unclaimed sequence  
FS PROTEIN SEQUENCE; STEREOSEARCH  
MF C19 H34 N4 O5 S  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

Absolute stereochemistry.




3 REFERENCES IN FILE CA (1907 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 4 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 257637-28-8 REGISTRY  
ED Entered STN: 01 Mar 2000  
CN L-Arginine, L-arginyl-L-isoleucyl-L-prolyl- (9CI) (CA INDEX NAME) PDX  
OTHER NAMES:  
CN 1: PN: US6022855 SEQID: 10 claimed sequence  
CN 2: PN: US20040127396 SEQID: 2 unclaimed sequence  
FS PROTEIN SEQUENCE; STEREOSEARCH  
MF C23 H44 N10 O5  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Search done by Noble Jarrell

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 5 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 151769-16-3 REGISTRY  
ED Entered STN: 16 Dec 1993  
CN Proteinase, pro-tumor necrosis factor (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN ADAM17 proteinase  
CN Metalloprotease TACE  
CN Metalloproteinase ADAM17  
CN Pro tumor necrosis factor cleavage enzyme  
CN Pro-tumor necrosis factor- $\alpha$ -processing enzyme  
CN **TACE**  
CN TACE proteinase  
CN TNF- $\alpha$  convertase  
CN TNF- $\alpha$  converting enzyme  
CN TNF- $\alpha$  processing protease  
CN Tumor necrosis factor  $\alpha$  convertase  
CN Tumor necrosis factor- $\alpha$  converting enzyme  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: BIOSIS, BIOTECHNO, CA, CAPLUS, CIN, EMBASE, TOXCENTER, USPAT2, USPATFULL

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

490 REFERENCES IN FILE CA (1907 TO DATE)  
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
495 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 6 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 147172-61-0 REGISTRY  
ED Entered STN: 23 Apr 1993  
CN Aggrecanase (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN ADAMTS-2  
CN ADAMTS-4  
CN Aggrecan-degrading metalloproteinase  
CN Aggrecan-degrading metalloproteinase ADAMTS4  
CN Aggrecan-degrading metalloproteinase MDTs6  
CN Aggrecanase 1  
CN Metalloproteinase ADAMTS-2

Search done by Noble Jarrell

CN Metalloproteinase ADAMTS-4  
CN Proteinase ADAMTS-2  
CN Proteinase ADAMTS-4  
ENTE A cartilage proteinase  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: AGRICOLA, BIOSIS, BIOTECHNO, CA, CAPLUS, CEN, CIN, EMBASE,  
PROMT, TOXCENTER, USPAT2, USPATFULL

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

283 REFERENCES IN FILE CA (1907 TO DATE)  
3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
288 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 7 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 146480-35-5 REGISTRY  
ED Entered STN: 17 Mar 1993  
CN Gelatinase A (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 72 kDa Gelatinase  
CN 72 kDa Gelatinase type A  
CN 72,000-Mol.-wt. gelatinase  
CN 72,000-Mol.-wt. type IV collagenase  
CN Collagenase IV  
CN Collagenase type IV  
CN E.C. 3.4.24.24  
CN Matrix metalloprotease 2  
CN Matrix metalloproteinase 2  
CN MMP 2  
CN Type IV collagen metalloproteinase  
CN Type IV collagenase  
CN Type IV collagenase/gelatinase  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO,  
CA, CAPLUS, CEN, CHEMCATS, CIN, EMBASE, PROMT, TOXCENTER, USPAT2,  
USPATFULL

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

\*\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*\*

5383 REFERENCES IN FILE CA (1907 TO DATE)  
14 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
5407 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 8 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 141760-45-4 REGISTRY  
ED Entered STN: 12 Jun 1992  
CN Furin (enzyme) (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN Furin  
CN PACE  
CN PACE-furin protease  
CN Paired basic amino acid cleaving enzyme  
CN Paired basic amino acid converting enzyme  
CN Saccharomyces cerevisiae gene QDS1 proteinase  
CN Serine proteinase PACE  
DR 144131-39-5  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: ADISNEWS, AGRICOLA, BIOBUSINESS, BIOSIS, CA, CAPLUS, CEN,  
CIN, IPA, PIRA, PROMT, TOXCENTER, USPAT2, USPATFULL

## \*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

704 REFERENCES IN FILE CA (1907 TO DATE)

9 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

705 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 9 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN

RN 99676-46-7 REGISTRY

ED Entered STN: 12 Jan 1986

CN Kex1a (9CI) (CA INDEX NAME)

## OTHER NAMES:

CN Adrenorphin-Gly-generating enzyme

CN Conversion endoprotease PC1

CN Convertase PC1

CN Dibasic endopeptidase

CN Dibasic processing protease

CN Dynorphin A-17 processing enzyme

CN E.C. 3.4.21.61

CN Endopeptidase Krp1

CN Endoprotease PC1/3

CN Endoprotease PC3

CN Endoproteinase Kex2p

CN Gene KEX2 dibasic proteinase

CN Kex 2p proteinase

CN Kex2 endopeptidase

CN Kex2 endoprotease

CN Kex2 endoproteinase

CN Kex2 protease

CN Kex2 proteinase

CN Kex2-like endoproteinase

CN Kex2-like precursor protein processing endoprotease

CN Krp1 endopeptidase

CN Neuroendocrine convertase 1

CN PC1 proteinase

CN PC3 precursor-processing proteinase

CN Proconvertase 1

CN Prohormone convertase

CN Prohormone convertase 1

CN Prohormone convertase 3

CN Prohormone convertase I

CN Prohormone convertase PC1

CN Prohormone convertase PC3

CN Prohormone-processing endoprotease

CN Prohormone-processing KEX2 proteinase

CN Prohormone-processing proteinase

CN Proprotein convertase

CN Proprotein convertase Kex2p

CN Proprotein convertase PC1

CN Protease KEX2

CN Proteinase Kex2p

CN Proteinase PC1

CN Proteinase, prohormone-processing

MF Unspecified

CI MAN

SR CA

LC STN Files: AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, CA, CAPLUS, CIN,  
EMBASE, PROMT, TOXCENTER, USPAT2, USPATFULL

## \*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

1071 REFERENCES IN FILE CA (1907 TO DATE)

13 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

1074 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 10 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN

RN 9041-92-3 REGISTRY

ED Entered STN: 16 Nov 1984



CN Trypsin inhibitor,  $\alpha$ 1- (9CI) (CA INDEX NAME) *Mutant PDX*  
OTHER NAMES:  
CN  $\alpha$ 1-Protease inhibitor  
CN  $\alpha$ 1-Antiprotease  
CN  $\alpha$ 1-Antiproteinase  
CN  $\alpha$ 1-Antitrypsin  
CN  $\alpha$ 1-Antitrypsin Pittsburgh mutant  
CN  $\alpha$ 1-Antitrypsin Portland  
CN  $\alpha$ 1-AT  
CN  $\alpha$ 1-Protease inhibitor  
CN  $\alpha$ 1-Proteinase inhibitor  
CN  $\alpha$ 1-Trypsin inhibitor  
CN Antitrypsin Pittsburgh  
CN Prolastin  
CN Respitin  
CN SERPINAL  
DR 9082-50-2, 124542-00-3  
MF Unspecified  
CI COM, MAN  
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS,  
BIOSIS, BIOTECHNO, CA, CAPLUS, CBNB, CEN, CHEMCATS, CHEMLIST, CIN,  
CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB,  
IMSCOSEARCH, IMSRESEARCH, IPA, MRCK\*, NIOSHTIC, PHAR, PROMT, RTECS\*,  
TOXCENTER, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)  
Other Sources: EINECS\*\*  
(\*\*Enter CHEMLIST File for up-to-date regulatory information)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5514 REFERENCES IN FILE CA (1907 TO DATE)  
311 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
5525 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> b wpix

~~FILE WPIFV~~ ENTERED AT 15:29:01 ON 08 JUN 2005  
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE LAST UPDATED: 3 JUN 2005 <20050603/UP>  
MOST RECENT DERWENT UPDATE: 200535 <200535/DW>  
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,  
PLEASE VISIT:  
[http://www.stn-international.de/training\\_center/patents/stn\\_guide.pdf](http://www.stn-international.de/training_center/patents/stn_guide.pdf) <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE  
<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER  
GUIDES, PLEASE VISIT:  
<http://thomsonderwent.com/support/userguides/> <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT  
DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX  
FIRST VIEW - FILE WPIFV.  
FOR FURTHER DETAILS: <http://www.thomsonderwent.com/dwpifv> <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.  
PLEASE CHECK:  
<http://thomsonderwent.com/support/dwpioref/reftools/classification/code-revision/>  
FOR DETAILS. <<<

=> d all 15 tot

L5 ANSWER 1 OF 1 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN  
AN 2002-395072 [43] WPIX  
DNC C2002-111283  
TI Treating inflammatory or erosive disease e.g. rheumatoid arthritis  
comprises administering alpha-one antitrypsin inhibitor variant.  
DC B04  
IN DUBOIS, C  
PA (UYSH) UNIV SHERBROOKE; (DUBO-I) DUBOIS C  
CYC 2  
PI CA 2312109 A1 20011223 (200243)\* EN 50 A61K038-43 <--  
US 2004127396 A1 20040701 (200444) A61K038-17 <--  
ADT CA 2312109 A1 CA 2000-2312109 20000623; US 2004127396 A1 Provisional  
US 2000-213995P 20000626, US 2001-885914 20010622  
PRAI CA 2000-2312109 20000623  
IC ICM A61K038-17; A61K038-43  
ICS A61K038-16; A61K048-00; A61P019-00; A61P029-00  
AB CA 2312109 A UPAB: 20020709  
NOVELTY - Treating inflammatory or erosive disease involving furin or  
furin-like protease activity comprises administering a compound selected  
from PDX (serpin alpha 1-antitrypsin inhibitor variant) or construct,  
variant, analog, PDX-related peptide, PDX-related peptidomimetic, their  
salts, complexes or derivatives.  
ACTIVITY - Antiinflammatory; Antirheumatic; Antiarthritic.  
MECHANISM OF ACTION - Furin and furin-like protease inhibitor.  
Furin-mediated endoproteolytic activation of TGF (transforming growth  
factor), PDGF (platelet derived growth factor), TACE (tumor necrosis  
factor (TNF- alpha ) converting enzyme), and aggrecanase-1 blocker.  
USE - Used for treating inflammatory or erosive disease, e.g.  
rheumatoid arthritis (claimed) and matrix remodelling conditions in a  
mammal.  
ADVANTAGE - PDX and its related compounds mimic the minimum consensus  
sequence (R-X-X-R) required for furin recognition and are potent furin  
inhibitors in vitro and in cells.  
Dwg.0/9  
FS CPI  
FA AB; DCN  
MC CPI: B04-C01; B14-C03; B14-C06; B14-C09

=> b home

FILE 'HOME' ENTERED AT 15:29:06 ON 08 JUN 2005

=>